The total return over the past 12 months is +8.91% vs. +16.94% for the S&P 500. So far it's up -19.60% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | +8.91% | (27.40%) | (70.04%) | (48.70%) | N/A | N/A |
| Total Return CAGR | +8.91% | (27.40%) | (70.04%) | (48.70%) | N/A | N/A |
| Revenue CAGR | (86.62%) | (84.84%) | (60.88%) | (21.34%) | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Avalo Therapeutics, Inc. (AVTX)
| Year | Start price | End price | AVTX Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $18.16 | $14.60 | (19.60%) | +14.51% | (34.11%) |
| 2025 | $7.43 | $18.16 | +144.42% | +17.72% | +126.70% |
| 2024 | $9.10 | $7.43 | (18.35%) | +24.89% | (43.24%) |
| 2023 | $1,209.60 | $9.10 | (99.25%) | +26.19% | (125.44%) |
| 2022 | $4,896.00 | $1,209.60 | (75.29%) | (18.17%) | (57.12%) |
| 2021 | $7,603.20 | $4,896.00 | (35.61%) | +28.74% | (64.35%) |
| 2020 | $15,523.20 | $7,603.20 | (51.02%) | +18.37% | (69.39%) |
| 2019 | $9,302.40 | $15,523.20 | +66.87% | +31.22% | +35.65% |
| 2018 | $9,216.00 | $9,302.40 | +0.94% | (4.56%) | +5.50% |
| 2017 | $2,534.40 | $9,216.00 | +263.64% | +21.70% | +241.94% |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
